Skip to main content
Swing Capital

Kilitch Drugs (India) Ltd

NSE: KILITCH BSE: 524500Pharma

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

₹170
52W: ₹117 — ₹250
PE 18.4 · Book ₹95.2 · +79% vs book
Market Cap₹594 Cr
Stock P/E18.4Price to Earnings
ROCE12.2%Return on Capital
ROE11.1%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has delivered good profit growth of 44.1% CAGR over last 5 years
  • +Company's median sales growth is 21.4% of last 10 years

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 10.2% over last 3 years.
  • −Earnings include an other income of Rs.13.8 Cr.
  • −Company has high debtors of 227 days.
  • −Promoter holding has decreased over last 3 years: -4.48%
  • −Working capital days have increased from 84.5 days to 172 days

Shareholding Pattern

Promoters63.77%
FIIs0%
DIIs0%
Public36.22%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters69.23%69.23%69.23%69.23%69.23%63.77%▼5.563.77%63.77%
FIIs0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%
Public30.77%30.77%30.76%▼0.030.77%▲0.030.77%36.22%▲5.436.23%▲0.036.22%▼0.0

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales30393345475634384572
Expenses26343040384231343952
Operating Profit453681444619
OPM %13%13%10%12%17%25%10%10%13%27%
Net Profit644971159514
EPS ₹1.571.041.162.531.973.251.372.491.44

AI Insights

Revenue Trend

Mar 2026 revenue at ₹189Cr, up 3.8% YoY. OPM at 17%.

Debt Position

Borrowings at ₹88Cr. Debt-to-equity ratio: 0.30x. Healthy balance sheet.

Capex Cycle

CWIP at ₹140Cr (700% of fixed assets). Significant capex underway — growth runway building.

Institutional Flow

DIIs: 0% (+0.00pp change). FIIs: 0% (+0.00pp change). Promoters hold 63.77%.

Margin & Efficiency

ROCE improving from -1% (Mar 2015) to 12% (Mar 2026). Working capital days: 172.

Valuation

PE 18.4x with 12.2% ROCE. Price is 79% above book value of ₹95.2. Dividend yield: 0%.

Recent Announcements